BBNX - NASDAQ
Beta Bionics, Inc.
$13.46
+5.3%Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes. It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.
At a Glance
Live SnapshotBeta Bionics, Inc. Management Team
Mr. Mark Hopman M.B.A., R.Ph.
Chief Commercial Officer
Compensation
$559,533
Mr. Stephen H. Feider
Chief Financial Officer, Treasurer & Secretary
Compensation
$659,583
Dr. Steven Russell M.D., Ph.D.
Chief Medical Officer
Mr. Mike Mensinger
Chief Product Officer
Blake Beber
Head of Investor Relations
Mr. Sean T. Saint PE
President, Chief Executive Officer & Director
Compensation
$885,667
Mr. Kevin Meinert
Vice President of Legal & Business Development
Ms. Karen Hynes M.B.A.
Vice President of Marketing
Mr. David Henderson
Vice President of Operations
Beta Bionics, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.24M worth of BBNX shares, with no buying activity reported.
3 Months
0
0.00
41.5K
513.49K
-513K
-$513K
3-6 Months
0
0.00
17.5K
378.76K
-379K
-$379K
6-9 Months
0
0.00
12.0K
350.89K
-351K
-$351K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Mensinger Mike
Officer: Chief Product Officer
$379K
Saint Sean
Director, Officer: President & Ceo
$351K
Hopman Mark
Officer: Chief Commercial Officer
$170K
Feider Stephen
Officer: Chief Financial Officer
$144K
Russell Steven Jon
Officer: Chief Medical Officer
$96K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.24M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
BBNX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | May 21, 2026 | 2026 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.